The Swiss Systemic lupus erythematosus Cohort Study (SSCS) - cross-sectional analysis of clinical characteristics and treatments across different medical disciplines in Switzerland.

Details

Ressource 1Download: 25115978.pdf (534.87 [Ko])
State: Serval
Version: Final published version
Serval ID
serval:BIB_2974FF159755
Type
Article: article from journal or magazin.
Collection
Publications
Title
The Swiss Systemic lupus erythematosus Cohort Study (SSCS) - cross-sectional analysis of clinical characteristics and treatments across different medical disciplines in Switzerland.
Journal
Swiss Medical Weekly
Author(s)
Ribi C., Trendelenburg M., Gayet-Ageron A., Cohen C., Dayer E., Eisenberger U., Hauser T., Hunziker T., Leimgruber A., Lindner G., Koenig K., Otto P., Spertini F., Stoll T., Von Kempis J., Chizzolini C.
Working group(s)
Swiss Systemic Lupus Erythematosus Cohort Study Group
ISSN
1424-7860
ISSN-L
0036-7672
Publication state
Published
Issued date
2014
Peer-reviewed
Oui
Volume
144
Pages
w13990
Language
english
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't Publication Status: epublish
Abstract
OBJECTIVES: To describe disease characteristics and treatment modalities in a multidisciplinary cohort of systemic lupus erythematosus (SLE) patients in Switzerland.
METHODS: Cross-sectional analysis of 255 patients included in the Swiss SLE Cohort and coming from centres specialised in Clinical Immunology, Internal Medicine, Nephrology and Rheumatology. Clinical data were collected with a standardised form. Disease activity was assessed using the Safety of Estrogens in Lupus Erythematosus National Assessment-SLE Disease Activity Index (SELENA-SLEDAI), an integer physician's global assessment score (PGA) ranging from 0 (inactive) to 3 (very active disease) and the erythrocyte sedimentation rate (ESR). The relationship between SLE treatment and activity was assessed by propensity score methods using a mixed-effect logistic regression with a random effect on the contributing centre.
RESULTS: Of the 255 patients, 82% were women and 82% were of European ancestry. The mean age at enrolment was 44.8 years and the median SLE duration was 5.2 years. Patients from Rheumatology had a significantly later disease onset. Renal disease was reported in 44% of patients. PGA showed active disease in 49% of patients, median SLEDAI was 4 and median ESR was 14 millimetre/first hour. Prescription rates of anti-malarial drugs ranged from 3% by nephrologists to 76% by rheumatologists. Patients regularly using anti-malarial drugs had significantly lower SELENA-SLEDAI scores and ESR values.
CONCLUSION: In our cohort, patients in Rheumatology had a significantly later SLE onset than those in Nephrology. Anti-malarial drugs were mostly prescribed by rheumatologists and internists and less frequently by nephrologists, and appeared to be associated with less active SLE.
Pubmed
Web of science
Open Access
Yes
Create date
09/10/2014 18:27
Last modification date
08/05/2019 16:12
Usage data